ProtoKinetix Stock

ProtoKinetix Equity Ratio

The Equity Ratio of ProtoKinetix (PKTX) as of Aug 23, 2026 is 73.39 %. In the previous year, Equity Ratio was 90.70 % — a change of -19.09% (lower).

Equity Ratio

73.39 %

YoY

-19.09%

Last updated:

Equity Ratio of ProtoKinetix is 2026 73.39 % . Equity Ratio of ProtoKinetix was 2025 90.70 % . It decreases by -19.09% lower compared to the previous year.

The ProtoKinetix Equity Ratio history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity Ratio
Date
Equity Ratio
Jan 1, 2017
72.10 USD
Jan 1, 2018
75.72 USD
Jan 1, 2019
95.64 USD
Jan 1, 2020
90.42 USD
Jan 1, 2021
79.10 USD
Jan 1, 2022
91.03 USD
Jan 1, 2023
90.70 USD
Jan 1, 2024
73.39 USD
The ProtoKinetix Equity Ratio history
YEAREquity RatioYoY
73.39 %-19.09%
90.70 %-0.36%
91.03 %+15.08%
79.10 %-12.52%
90.42 %-5.47%
95.64 %+26.32%
75.72 %+5.02%
72.10 %-21.33%
91.64 %+1.93%
89.91 %-101.22%
-7,367.20 %
Access this data via the Eulerpool API

ProtoKinetix Stock analysis

What does ProtoKinetix do? ProtoKinetix Inc. is a Canadian biotechnology company focused on the development of glycoproteins for therapeutic applications. The company was founded in 2005 and is headquartered in Marietta, USA. ProtoKinetix specializes in the research and development of AAGP® (Anti-Aging Glycopeptide) as biopharmaceuticals. These proprietary glycoproteins have the ability to protect cells and can be used in various therapeutic applications for improving damage in physical injury, spinal cord injury, diabetes, transplantation, and retinal diseases. In addition to the medical field, ProtoKinetix is also developing its patented technology for use in bio-agriculture and animal healthcare. It has a subsidiary that holds the rights to use and distribute AAGP® and its patents. ProtoKinetix's business model involves licensing its glycoprotein technology for various applications, including biopharmaceuticals, bioprocessing industries, and cell protection management for regenerative medicine and stem cell preparations. The company has established partnerships with other biotech companies to integrate its AAGP® technology into their product pipelines. ProtoKinetix's flagship product is the AAGP® protein solution, which is used as a medication in regenerative medicine, organ transplantation, eye healing, and animal health. It is also interested in researching the application of AAGP® in crop farming to increase yields and improve soil quality. ProtoKinetix is poised to play a significant role in the development of glycoproteins as future medicines and therapeutic technologies in various industries. It not only has the potential to explore healing medical products but also aims to enhance agriculture and animal care. ProtoKinetix represents an excellent example of a biotechnology company focused on improving the healthcare and agricultural industries. ProtoKinetix is one of the most popular companies on Eulerpool.

Frequently Asked Questions about ProtoKinetix stock

Equity Ratio of ProtoKinetix is 73.39 % in 2026.

Equity Ratio of ProtoKinetix changed from 90.70 % to 73.39 %, representing a -19.09% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Equity Ratio ProtoKinetix since 2006 – with annual values, charts, and detailed analysis.

The equity ratio measures the proportion of total assets financed by shareholders' equity. Higher ratios indicate stronger financial independence and lower leverage.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Equity Ratio's ProtoKinetix with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Leverage — ProtoKinetix

All Key Metrics — ProtoKinetix